Value of health futureproofing healthcare
Transforming health
Download and listen at Apple
You are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
Or Watch on YouTube
You are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
-
Benelux
Local challenges & incentives for innovative healthcareListen nowYou are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
-
France
Importance of Early Access ProgrammesListen nowYou are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
-
Switzerland
Challenges for Europe as a hub for pharmaceutical innovationListen nowYou are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
-
Nordics
Strategic partnerships to tackle healthcare challengesListen nowYou are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
-
Italy
Next generation of healthcare professionals in ItalyListen nowYou are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
-
Central Europe & Baltics
Challenges in management, access, & patient outcomesListen nowYou are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
The Value of Health
-
V4_HIGHLIGHT_EP1_JOHNSON & JOHNSON_MAINSHOW.mp4V4_HIGHLIGHT_EP1_JOHNSON & JOHNSON_MAINSHOW.mp4
-
Highlights Developing resilient, sustainable and excellent health systems 25.mp4Highlights Developing resilient, sustainable and excellent health systems 25.mp4
-
Highlights - Investing in the future of health ’25.mp4Highlights - Investing in the future of health ’25.mp4
Articles
-
Optimising Investment in Health Innovations in Europe
Read moreYou are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
-
The economic power of healthy populations
Read moreYou are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
-
Europe is at a crossroads in health policy
Read moreYou are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
-
Can Europe restore its edge in healthcare innovation?
Read moreYou are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
-
Time to act: closing the innovation gap in myasthenia gravis
Read moreYou are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
-
Why the future of European healthcare depends on greater investment
Read moreYou are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
-
Valuing preventative interventions in HTA: the impact of discounting practices
Read moreYou are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
Podcasts
-
J&J’s Martin Price on World Cancer Day 2025 – Part 1
Listen/WatchYou are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
-
J&J’s Martin Price on World Cancer Day 2025 – Part 2
Listen/WatchYou are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
Are Health Technology Assessments fit to judge the value of cell and gene therapies?
You are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
Access and pricing principles
We help navigate increasingly complex healthcare systems and continue to work to enable local patient access to transformational medical innovation now and in the future.
Three guiding principles drive our pricing decisions.
-
Local Value
The value our medicines bring is in improving the lives of patients and transforming their health for the future.
We strive to deliver transformational medicines that improve the lives and health of patients. Our medicines help people live longer and improve their quality of life. We work closely with payers such as governments, insurers and other local stakeholders to negotiate the price of our medicines based on their local value — prioritizing health outcomes and the impact our medicines have on a specific society and economy. -
Sustainable Innovation
Sustaining the discovery, development and delivery of transformational medicines is necessary to improve lives for current and future patients in need.
When we succeed at delivering valuable medicines with transformational outcomes, individual patients thrive, and families, countries, communities and societies flourish. Enabling investment in innovation to discover, develop and deliver medicines provides significant benefit to patients today and tomorrow. Fair pricing for valuable therapies fuels the next breakthroughs and cures. -
Accessible & Affordable
Through active collaboration, we make our medicines readily accessible and affordable for patients and health systems in accordance with specific reimbursement systems and legal guidelines of local communities.
Countries and health systems around the world differ in how they pay for medicines and make them accessible to their citizens. Knowing this, we work with governments and payers, as early as the law allows, to discuss coverage, accelerate availability and provide the best possible access to our medicines. After all, medicines only deliver value when they reach patients who need them.